VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of a new Frequently Asked Questions (“FAQ”) page on its corporate website. The new FAQ resource, available at www.izocorp.c ...

Core Insights - The BioMedWire Podcast features an interview with Robert Thast, CEO of Izotropic Corp, focusing on the company's innovative technologies for breast cancer screening and diagnosis [2][3][4] Company Overview - Izotropic Corp is a medical device company that is commercializing the IzoView Breast CT Imaging System, which aims to improve early cancer detection by identifying cancers as small as 2 millimeters, compared to the current standard of care that averages 11 millimeters [3][4] Technology and Innovation - The company has developed unique AI capabilities that are expected to gain acceptance in the market, potentially making Izotropic a target for acquisition by larger firms [5] - Izotropic's intellectual property strategy includes a portfolio of patents and trade secrets to protect its innovations in the imaging space [5] Market Strategy - The commercialization strategy involves a phased rollout of the IzoView system, starting in Europe and then expanding to the U.S., targeting hospitals, medical facilities, and imaging clinics [6] - The combined U.S. and European markets represent nearly 50% of the global market for breast imaging devices [6] Future Outlook - Securing FDA approval is seen as a critical milestone that would open up significant market opportunities for Izotropic [6]

Core Insights - Izotropic Corporation has announced the issuance of the only U.S. patent for computer-aided diagnosis (CADx) with breast CT, which is covered by an exclusive global license agreement with the Regents of the University of California [1] - The IzoView Breast CT Imaging System is being positioned as a 3D imaging alternative that enhances breast cancer screening, particularly for patients with dense breast tissue [3] - CADx will be integrated into the IzoView system post-market launch as a software upgrade, potentially offered as an incentive to early adopters [5] Company Overview - Izotropic Corporation specializes in medical devices and innovative technologies aimed at improving breast cancer screening, diagnosis, and treatment [1][6] - The company is focused on commercializing the IzoView Breast CT Imaging System, which utilizes a machine-learning image reconstruction algorithm to optimize imaging while maintaining low radiation doses [4] Technology and Market Position - CADx is an AI-based tool designed to assist radiologists in interpreting medical images, addressing limitations of existing imaging modalities like mammography and ultrasound [2] - The integration of CADx aims to enhance diagnostic performance, reduce read times, and improve overall efficiency in clinical workflows [2]

  - Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT - - Trained on 15 years of specialized breast CT data and protected as a trade secret, giving Izotropic a durable competitive edge - - AI enhances IzoView’s image quality by reducing CT image noise without increasing radiation dose - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) ( ...

- Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT - - Trained on 15 years of specialized breast CT data and protected as a trade secret, giving Izotropic a durable competitive edge - - AI enhances IzoView’s image quality by reducing CT image noise without increasing radiation dose - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (F ...

Core Insights - Izotropic Corporation has launched BreastCT.com, an online platform aimed at increasing awareness of its IzoView Breast CT Imaging System, which targets challenges in detecting breast cancer in women with dense breast tissue [1][2]. Company Overview - Izotropic Corporation is a medical device company focused on innovative technologies for breast cancer screening, diagnosis, and treatment [1]. - The IzoView Breast CT Imaging System is designed to improve detection rates in the 50% of women with dense breast tissue [2]. Product and Market Positioning - BreastCT.com serves as an educational resource on dedicated breast CT technology and the IzoView system, positioning the company within a broader industry context [2][3]. - The platform aims to build recognition for IzoView Breast CT ahead of regulatory and commercial milestones by highlighting successful public companies in the imaging sector [3]. Marketing Strategy - The company plans to integrate native advertising campaigns into BreastCT.com to enhance awareness and align with its strategic goals [4].

Core Insights - Izotropic Corporation has launched BreastCT.com, an online platform aimed at increasing awareness of its IzoView Breast CT Imaging System, which targets challenges in detecting breast cancer in women with dense breast tissue [1][2]. Company Overview - Izotropic Corporation is a medical device company focused on innovative technologies for breast cancer screening, diagnosis, and treatment [1]. - The IzoView Breast CT Imaging System has completed its engineering phase and is positioned to evolve through clinical studies and regulatory processes [2]. Industry Context - The launch of BreastCT.com positions Izotropic within a broader industry context by comparing it to other public companies that have successfully developed new imaging technologies, thereby enhancing recognition of IzoView Breast CT in the market [3]. Marketing Strategy - The company plans to integrate native advertising campaigns into BreastCT.com at strategic times to align with its awareness goals [4].

Core Insights - Izotropic Corporation has launched a new corporate website and brand identity to enhance its market presence and communication strategy [1][2][3] Company Overview - Izotropic Corporation is a medical device company focused on innovative technologies and imaging products for breast cancer screening, diagnosis, and treatment [1][2] - The company’s flagship product is the IzoView Breast CT Imaging System, designed to meet current challenges in breast imaging [4] Website and Brand Identity - The redesigned website, izocorp.com, features a modern visual identity and streamlined navigation, aimed at engaging patients, clinicians, and stakeholders [2][3] - The new corporate tagline "Advanced Imaging. Accessible Care." reflects the company's commitment to scalable innovations in healthcare [3] Product Focus - The IzoView Breast CT Imaging System is highlighted with the tagline "Engineered for Today's Challenges and Tomorrow's Care Models," emphasizing its relevance to evolving industry trends [4] Engagement and Communication - Izotropic encourages investors, media, and stakeholders to explore the new website and follow the company's progress in the breast imaging market [5]

- IzoView optimized for AI-readiness, addressing a critical need as imaging centers adopt smart workflows and algorithmic support tools VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- via IBN - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides ...

Core Insights - The global breast imaging market is projected to grow from $5.4 billion in 2024 to $8.69 billion by 2030, reflecting a CAGR of 8.25% [2][8] - Izotropic Corporation's IzoView Breast CT Imaging System is positioned to lead in dense breast imaging, addressing the rising incidence of breast cancer and new screening mandates [1][13] - The adoption of AI in imaging workflows is critical, with over 100 AI algorithms approved by the FDA since early 2025, enhancing diagnostic accuracy and efficiency [10][19] Market Growth Projections - The U.S. breast imaging market is expected to expand from $1.0 billion in 2024 to $1.55 billion by 2030, with a CAGR of 7.57% [2][8] - Digital breast tomosynthesis (DBT) is forecasted to grow from approximately $950 million in 2024 to $1.71 billion by 2030, with a CAGR of 10.28% [11] - Breast ultrasound is projected to reach approximately $1.98 billion by 2030, growing at a CAGR of 8.85% [11] Technological Advancements - The industry is moving towards enhanced accuracy and personalized screening strategies, particularly for women with dense breast tissue, which constitutes about 50% of the female population [3][4] - IzoView offers true 3D imaging without compression, improving sensitivity in dense tissue compared to traditional mammography and DBT [14][20] - The integration of AI into breast imaging workflows is essential for improving diagnostic processes and patient outcomes [10][19] Regulatory and Policy Changes - Regulatory shifts, including FDA mandates for informing patients about breast density, are facilitating the adoption of advanced imaging technologies [9] - 38 states in the U.S. have mandated insurance coverage for supplemental screening, further supporting early detection initiatives [9] Patient Experience and Market Demand - There is a growing demand for non-compressive, faster, and more comfortable imaging procedures, which are influencing purchasing decisions in imaging centers [5][20] - IzoView's design focuses on patient comfort, offering a contact-free exam that could enhance screening compliance [20] Competitive Positioning - IzoView is uniquely positioned in the market, with a target sales price of $500K, significantly lower than existing breast CT systems priced at $1.2 million to $1.5 million [12][14] - The system's capabilities align with the industry's shift towards personalized imaging and individualized screening protocols, supported by a robust patent portfolio [16][17]